Literature DB >> 11489353

Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation.

N L Strominger1, R Brady, G Gullikson, D O Carpenter.   

Abstract

The immunomodulator, imiquimod, has been shown to have antiviral and antitumor properties in animal models. It also has been reported to alter cytokine levels in both animals and humans. However, because imiquimod appeared to be emetic, studies were conducted to determine the degree of sensitivity, and the pathways involved. Subcutaneous administration of > or = 10 mg/kg imiquimod to ferrets elicited emesis with latencies as short as 2'; 12 and 15 mg/kg were optimal doses. Emetic responsiveness was eliminated by complete ablation of the area postrema, but was unaffected by bilateral supradiaphragmatic section of the vagus nerve. This indicates that the emesis is produced by an activation of the chemoreceptor trigger zone B the area postrema. Ferret brain stem slices (450 microm) were preincubated in oxygenated Krebs-Ringer and then mounted in a submerged slice recording chamber. Extracellular recordings of spontaneous and ionophoretically evoked activity of area postrema neurons were obtained for up to 8 h, while the effect of bath-applied imiquimod was determined. Under control conditions, neurons showed a low frequency spontaneous discharge. Introduction of imiquimod (concentration range, 1 x 10(-7) to 5 x 10(-8)M) had no effect on neuronal firing. With ionophoresis of glutamate from an independent micropipette, a brief excitatory response was obtained. We conclude that imiquimod does not directly excite area postrema neurons. It is likely that imiquimod causes synthesis and release of some unknown emetic substance(s), very possibly cytokines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489353     DOI: 10.1016/s0361-9230(01)00539-1

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  6 in total

1.  Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.

Authors:  Alyson J Smith; Yufeng Li; Hélène G Bazin; Julien R St-Jean; Daniel Larocque; Jay T Evans; Jory R Baldridge
Journal:  Vaccine       Date:  2016-07-09       Impact factor: 3.641

2.  Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination.

Authors:  David J Dowling; Soumik Barman; Alyson J Smith; Francesco Borriello; Danielle Chaney; Spencer E Brightman; Gandolina Melhem; Byron Brook; Manisha Menon; Dheeraj Soni; Simone Schüller; Karthik Siram; Etsuro Nanishi; Hélène G Bazin; David J Burkhart; Ofer Levy; Jay T Evans
Journal:  Sci Rep       Date:  2022-10-18       Impact factor: 4.996

3.  Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method.

Authors:  Hélène G Bazin; Laura S Bess; Mark T Livesay; Sandra C Mwakwari; David A Johnson
Journal:  Tetrahedron Lett       Date:  2016-04-01       Impact factor: 2.415

4.  Efficient tin-mediated synthesis of lysophospholipid conjugates of a TLR7/8-active imidazoquinoline.

Authors:  Sandra C Mwakwari; Laura S Bess; Hélène G Bazin; David A Johnson
Journal:  Tetrahedron Lett       Date:  2016-04-01       Impact factor: 2.415

5.  Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model.

Authors:  Eric C Kauffman; Huixian Liu; Michael J Schwartz; Douglas S Scherr
Journal:  J Oncol       Date:  2012-02-22       Impact factor: 4.375

6.  Sex differences in morphine sensitivity are associated with differential glial expression in the brainstem of rats with neuropathic pain.

Authors:  Damien C Boorman; Kevin A Keay
Journal:  J Neurosci Res       Date:  2022-07-19       Impact factor: 4.433

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.